(Note: OS Acquisition Corp. withdrew its SPAC IPO in an SEC filing dated Nov. 9, 2022. The blank check company, or SPAC, filed its S-1 on March 24, 2021. Each unit consisted of one share of common stock and one-third of a warrant.)

OS Acquisition Corp. is a newly organized blank check company focused on healthcare technology.

Our sponsor is OS Acquisition Sponsor LLC, a Delaware limited liability company managed by OS Acquisition Management LLC, a Delaware limited liability company.

Jeff Klunzinger, co-founder of OS Fund, a leading venture firm, manages Acquisition Management. OS Fund focuses on commercializing scientific platform companies. It is an early leader in investing in synthetic biology and technology-enabled drug discovery. The firm has over 30 portfolio companies, and invests in computationally driven companies utilizing artificial intelligence, or AI, and machine learning to develop platform technologies in key areas, including genomics, synthetic biology, computationally-derived therapeutics, advanced materials and diagnostics.

Notable investments include Ginkgo Bioworks (biological engineering products and custom microbes), Atomwise (AI-powered drug discovery platform), Aria Pharmaceuticals (AI-driven drug discovery platform leveraging computational biology to identify promising drug candidates), Eat Just (plant-based alternatives to conventionally-produced chicken products, including meat and eggs), Synthego (full stack genome engineering solutions at scale), Lucira Health (point-of-care and at-home diagnostic kits, including the first FDA-authorized COVID-19 self-test for the at-home setting), Pivot Bio (microbiome-based alternatives to synthetic nitrogen fertilizer), Verge Genomics (next-generation drug discovery platform utilizing genomic and transcriptomic data to accelerate drug discovery for neurological diseases), and NuMat Technologies (metal-organic framework, or MOF, based solutions to the precision gas and storage markets).